Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms-Reference-Cited by-同舟云学术

Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms

Published:2020-07-16 Issue:7 Volume:15 Page:e0235815
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Cameron Beatrice,Dabdoubi Tarik,Berthou-Soulié Laurence,Gagnaire Marie^ORCID,Arnould Isabelle^ORCID,Severac Anne,Soubrier Fabienne,Morales Jacqueline,Leighton Philip A.^ORCID,Harriman William,Ching Kathryn^ORCID,Abdiche Yasmina,Radošević Katarina,Bouquin Thomas^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking;M Fukuda;J Biol Chem,1991

2. Characterization and cloning of lgp110, a lysosomal membrane glycoprotein from mouse and rat cells;BL Granger;J Biol Chem,1990

3. Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage;A Cohnen;Blood,2013

4. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells;V Sarafian;Int J Cancer,1998

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD8 T lymphocytes from B-1 cell-deficient mice down-regulates fungicidal activity of macrophages challenged with E. Cuniculi;Immunobiology;2024-07

2. Enabling site-specific NMR investigations of therapeutic Fab using a cell-free based isotopic labeling approach: application to anti-LAMP1 Fab;Journal of Biomolecular NMR;2024-03-28

3. Contribution of B-1 cells in the cytotoxicity of CD8 T lymphocytes in encephalitozoonosis;2023-11-22

4. Immunogenicity risk assessment of synthetic peptide drugs and their impurities;Drug Discovery Today;2023-10

5. Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics;Frontiers in Drug Discovery;2023-08-03